搜尋
Emergent BioSolutions Inc
EBS添加自選
7.220USD
-0.050-0.69%
收盤 07-31 16:00（美東）報價延遲15分鐘
372.53M總市值
虧損本益比TTM
關於 Emergent BioSolutions Inc 公司
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
Emergent BioSolutions Inc簡介
公司代碼EBS
公司名稱Emergent BioSolutions Inc
上市日期Nov 15, 2006
CEOPapa (Joseph C)
員工數量900
證券類型Ordinary Share
年結日Nov 15
公司地址300 Professional Dr
城市GAITHERSBURG
上市交易所NASDAQ OMX NASDAQ Basic NYSE
國家United States of America
郵編20879
電話12406313200
網址https://emergentbiosolutions.com/
公司代碼EBS
上市日期Nov 15, 2006
CEOPapa (Joseph C)
Emergent BioSolutions Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
304.82K
+61.58%
Mr. Richard S. (Rich) Lindahl
Mr. Richard S. (Rich) Lindahl
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
267.95K
-1.48%
Ms. Jessica Perl
Ms. Jessica Perl
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
165.29K
+63.09%
Ms. Coleen Glessner
Ms. Coleen Glessner
Executive Vice President - Quality and Ethics and Compliance
Executive Vice President - Quality and Ethics and Compliance
153.92K
-1.31%
Mr. William Hartzel
Mr. William Hartzel
Senior Vice President - Manufacturing and Bioservices
Senior Vice President - Manufacturing and Bioservices
145.03K
-1.20%
Dr. Simon C Lowry, M.D.
Dr. Simon C Lowry, M.D.
Chief Medical Officer, Head of Research and Development
Chief Medical Officer, Head of Research and Development
116.59K
+85.86%
Dr. Zsolt Harsanyi, Ph.D.
Dr. Zsolt Harsanyi, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
114.67K
+22.10%
Mr. Ronald B. Richard
Mr. Ronald B. Richard
Independent Director
Independent Director
89.36K
+28.36%
Mr. Marvin L. White
Mr. Marvin L. White
Independent Director
Independent Director
79.44K
+31.90%
Mr. Keith A. Katkin, CPA
Mr. Keith A. Katkin, CPA
Independent Director
Independent Director
59.03K
+16.71%
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
304.82K
+61.58%
Mr. Richard S. (Rich) Lindahl
Mr. Richard S. (Rich) Lindahl
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
267.95K
-1.48%
Ms. Jessica Perl
Ms. Jessica Perl
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
165.29K
+63.09%
Ms. Coleen Glessner
Ms. Coleen Glessner
Executive Vice President - Quality and Ethics and Compliance
Executive Vice President - Quality and Ethics and Compliance
153.92K
-1.31%
Mr. William Hartzel
Mr. William Hartzel
Senior Vice President - Manufacturing and Bioservices
Senior Vice President - Manufacturing and Bioservices
145.03K
-1.20%
Dr. Simon C Lowry, M.D.
Dr. Simon C Lowry, M.D.
Chief Medical Officer, Head of Research and Development
Chief Medical Officer, Head of Research and Development
116.59K
+85.86%
常見問題
Emergent BioSolutions Inc的前五大股東是誰？
Emergent BioSolutions Inc的前五大股東如下：Mr. Joseph C. (Joe) Papa
有多少機構持有Emergent BioSolutions Inc(EBS)的股份？
截至2026Q1，共有412家機構持有Emergent BioSolutions Inc的股份，合計持有的股份價值約為42.30M，占公司總股份的81.98% 。與2025Q4相比，機構持股有所增加，增幅為-3370363.00。
哪個業務部門對Emergent BioSolutions Inc的收入貢獻最大？
在2026Q1，Commercial Product sales業務部門對Emergent BioSolutions Inc的收入貢獻最大，創收223.30M，占總收入的30.06% 。